Interestingly, some studies have reported the lack of GLP-1R expression in hepatic cells [31], leading to the hypothesis that the effect of GLP-1R agonists on NAFLD is not mediated by direct GLP-1R activation. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.